B-cell function in subjects after stopping immunoglobulin replacement
| Subject/age, y . | Time after tx, y . | Serum IgG, mg/dL . | Serum IgA, mg/dL . | Serum IgM, mg/dL . | Serum IgE, IU/mL . | Other titers . |
|---|---|---|---|---|---|---|
| Subject 1* | ||||||
| 0.4 | −0.7 | 126 | < 22 | < 17 | 409 | |
| 4.0 | 2.8 | 761 | 68 | 104 | ||
| 4.2 | 3.0 | 775 | 93 | 80 | ||
| 4.3 | 3.1 | 686 | 93 | 103 | 13 | Tetanus titer (prevaccine): 1 μg/mL |
| 4.4 | 3.2 | Tetanus titer (postvaccine): 135 μg/mL | ||||
| 4.7 | 3.5 | 568 | 82 | 116 | ||
| 5.5 | 4.4 | 831 | 110 | 162 | ||
| Normal, age 4-6 y | 640-1420 | 52-220 | 40-180 | < 52 | ||
| Subject 2* | ||||||
| 0.4 | −0.3 | 292 | 15 | 55 | ||
| 2.1 | 1.4 | 477 | 26 | 99 | ||
| 2.1 | 1.4 | Tetanus titer: 1.24 IU/m†; hemophilus titer: 17.4 μg/mL (> 1†); polio #1: 15 (< 5‡); polio #2: > 160 (< 5‡); polio #3: 80 (< 5‡) | ||||
| 2.3 | 1.6 | 432 | 32 | 103 | ||
| 2.5 | 1.8 | 408 | 39 | 87 | ||
| 2.9 | 2.2 | 504 | 39 | 110 | ||
| 3.6 | 2.9 | 506 | 96 | 112 | HBs: 70 mIU/mL (< 10‡); rubella: 154 IU/mL (< 10‡) | |
| 3.6 | 2.9 | Anti-A: 1:32 (IgM)†; anti-B: 1:16 (IgM)† | ||||
| 3.7 | 2.9 | Mumps: 351 (< 50‡); measles: 265 (< 70‡) | ||||
| 3.7 | 2.9 | 7.7 IU/mL | ||||
| Normal, age 2 y | 582-1200 | 46-157 | 54-155 | 0-126 | ||
| Normal, age 3 y | 582-1200 | 46-157 | 54-155 | 3-135 |
| Subject/age, y . | Time after tx, y . | Serum IgG, mg/dL . | Serum IgA, mg/dL . | Serum IgM, mg/dL . | Serum IgE, IU/mL . | Other titers . |
|---|---|---|---|---|---|---|
| Subject 1* | ||||||
| 0.4 | −0.7 | 126 | < 22 | < 17 | 409 | |
| 4.0 | 2.8 | 761 | 68 | 104 | ||
| 4.2 | 3.0 | 775 | 93 | 80 | ||
| 4.3 | 3.1 | 686 | 93 | 103 | 13 | Tetanus titer (prevaccine): 1 μg/mL |
| 4.4 | 3.2 | Tetanus titer (postvaccine): 135 μg/mL | ||||
| 4.7 | 3.5 | 568 | 82 | 116 | ||
| 5.5 | 4.4 | 831 | 110 | 162 | ||
| Normal, age 4-6 y | 640-1420 | 52-220 | 40-180 | < 52 | ||
| Subject 2* | ||||||
| 0.4 | −0.3 | 292 | 15 | 55 | ||
| 2.1 | 1.4 | 477 | 26 | 99 | ||
| 2.1 | 1.4 | Tetanus titer: 1.24 IU/m†; hemophilus titer: 17.4 μg/mL (> 1†); polio #1: 15 (< 5‡); polio #2: > 160 (< 5‡); polio #3: 80 (< 5‡) | ||||
| 2.3 | 1.6 | 432 | 32 | 103 | ||
| 2.5 | 1.8 | 408 | 39 | 87 | ||
| 2.9 | 2.2 | 504 | 39 | 110 | ||
| 3.6 | 2.9 | 506 | 96 | 112 | HBs: 70 mIU/mL (< 10‡); rubella: 154 IU/mL (< 10‡) | |
| 3.6 | 2.9 | Anti-A: 1:32 (IgM)†; anti-B: 1:16 (IgM)† | ||||
| 3.7 | 2.9 | Mumps: 351 (< 50‡); measles: 265 (< 70‡) | ||||
| 3.7 | 2.9 | 7.7 IU/mL | ||||
| Normal, age 2 y | 582-1200 | 46-157 | 54-155 | 0-126 | ||
| Normal, age 3 y | 582-1200 | 46-157 | 54-155 | 3-135 |
tx indicates transplantation; and HBs, antibody to hepatitis B surface antigen.
Subject 1 stopped immunoglobulin replacement at 3.9 years of age, 2.7 years after transplantation; subject 2 stopped immunoglobulin replacement at 1.8 years of age, 1.1 years after transplantation.
Normal response.
Control value indicates absence of immunity.